ArticleJournal of inflammation research2025
Case-Control Study: Evaluating the Role and Therapeutic Potential of FSTL1 in Type 2 Inflammation of Chronic Rhinosinusitis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Therapeutic and Inflammation Biomarkers: The Role of Meteorin-Like (Metrnl) and Follistatin-Like 1 (FSTL1) in Inflammatory Diseases.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Follicle suppressor-like protein 1 (FSTL1) plays a contributory role in chronic inflammation, and it currently been demonstrated in studies of asthma and chronic obstructive pulmonary disease (COPD), but studies in chronic sinusitis with nasal polyps have not been addressed. The aim of this study was to explore the expression of follicle suppressor-like protein 1 (FSTL1) in chronic sinusitis and its possible association with type 2 inflammation. Patients and Methods: This study included 34 CRS patients (24 ECRS, 10 non-ECRS) and 10 controls. Hematoxylin-eosin (HE) staining to observe the pathomorphological changes of these three groups of tissue specimens in detail, Immunohistochemistry (IHC), real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) technology and Western blotting (WB) were used to evaluate the expression levels of FSTL1 and type 2 inflammatory cytokines IL-4, IL-5, and IL-13 in the three groups. Results: In the ECRS group, there was thickening of the tissue mucosa and hyperplasia of glands, along with a significant infiltration of inflammatory cells and eosinophils. The experimental results showed that the expression levels of FSTL1 and type 2 inflammatory cytokines IL - 4, IL - 5, and IL - 13 were higher in the ECRS and non - ECRS groups than in the control group (P<0.05). Additionally, FSTL1 and IL-4, IL-5, IL-13 were positively correlated in the ECRS group(P<0.05). Conclusion: FSTL1, IL-4, IL-5 and IL-13 were highly expressed in chronic sinusitis, and FSTL1 was positively correlated with IL-4, IL-5 and IL-13 in the ECRS group, suggesting that FSTL1 contributes to the development of type 2 inflammation in ECRS, and FSTL1 may serve as a potential therapeutic target for ECRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.